Sign Up to like & get
recommendations!
1
Published in 2017 at "Diabetes Therapy"
DOI: 10.1007/s13300-017-0248-5
Abstract: AbstractIntroduction Sodium glucose co-transporter 2 (SGLT2) inhibitors increase urinary glucose excretion (UGE) by reducing the renal threshold for glucose excretion, which results in decreased serum glucose concentrations in patients with type 2 diabetes mellitus (T2D).…
read more here.
Keywords:
sglt2 inhibitor;
urinary glucose;
morning spot;
morning ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "ACS Omega"
DOI: 10.1021/acsomega.2c06483
Abstract: (1) Purpose: To develop a mathematical model combining physiologically based pharmacokinetic and urinary glucose excretion (PBPK-UGE) to simultaneously predict pharmacokinetic (PK) and UGE changes of luseogliflozin (LUS) as well as to explore the role of…
read more here.
Keywords:
urinary glucose;
reabsorption;
glucose;
explore role ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2019 at "Diabetes"
DOI: 10.2337/db19-2354-pub
Abstract: The renoprotective effect through the tubuloglomerular feedback mechanism (TGF) with the Sodium-glucose cotransporter2 inhibitor (SG) attracts attention. We investigated whether the improvement of TGF can be estimated from urinary glucose (UG) and urinary sodium (UNa)…
read more here.
Keywords:
improvement tgf;
urinary glucose;
sodium;
excretion ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2017 at "Annals of Laboratory Medicine"
DOI: 10.3343/alm.2017.37.1.9
Abstract: Background With the advent of sodium glucose co-transporter 2 inhibitors to control glucose and treat diabetes, laboratory data aided by either timed or spot glucose levels in the urine could be used as an alternative…
read more here.
Keywords:
overnight urinary;
spot;
urine;
morning spot ... See more keywords